Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,longTermDebt,accountsPayable,otherCurrentAssets,netReceivables,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,netBorrowings,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,priceHint,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,exchangeDataDelayedBy,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,FREQ,177407000.0,34219200,15106000,,-20375000,,-20375000,9744000,4651000,-20199000,-20199000,,-218000,,,,0,4651000,24850000,0,-176000,,-20375000,-20375000,293137000.0,64104000.0,177407000.0,9710000.0,241511000.0,34000.0,-115774000.0,10000.0,1823000.0,169227000.0,18918000.0,10000.0,39611000.0,200077000.0,25682000.0,15000000.0,5452000.0,,,-25666000.0,-6497000.0,-26209000.0,572000.0,-3881000.0,572000.0,-51111000.0,-25474000.0,382000.0,4897000.0,-543000.0,,,181159000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,-1.61,-4.9130435,-25.04,7.981111,-0.0711112,-0.008909938,15.786522,-7.876522,-0.49893966,270673856,-18.395348,-0.31589454,15,America/New_York,EDT,-14400000,False,False,7.91,1630526402,0.19000006,7.8,7.915,7.63,107722,POST,NMS,2,0.0,1630526407,7.91,0.0,2.4611409,7.63 - 7.915,7.72,7.84,8.1,11,10,finmb_416409020,NasdaqGS,"Frequency Therapeutics, Inc.",USD,336321,150450,1.0549998,0.15390223,6.855 - 58.37,-50.46,-0.8644852,6.855,58.37,1617048000,1617048000,1617048000,-10.293,-0.43,0,"Frequency Therapeutics, Inc.",,,,58.37,6.86,7.98,15.79,336.32k,150.45k,34.22M,,29.78M,12.31%,60.44%,5.98M,14,24.37%,17.47%,5.44M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-122.12%,-122.47%,-11.51%,-24.53%,34.37M,1.04,-36.00%,36.98M,-40.78M,-41.97M,-10.29,,194.91M,5.7,46.48M,26.20,10.58,-25.04,-61.3M,-46.61M,Value,02421,Healthcare,83,9,1,"Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.",Lexington,781 315 4600,MA,8,1609372800,1625011200,8,United States,http://www.frequencytx.com,86400,8,75 Hayden Avenue,Biotechnology,Suite 300
t-1,FREQ,192491000.0,34219200,10436000,,-10257000,,-10232000,9791000,9950000,-10277000,-10277000,,-218000,,,,-25000,9950000,20227000,0,20000,,-10232000,-10232000,287829000.0,72231000.0,192491000.0,14148000.0,264722000.0,34000.0,-95399000.0,27000.0,1820000.0,220341000.0,26634000.0,27000.0,37838000.0,225064000.0,,15000000.0,5506000.0,1831000.0,2892000.0,-17000.0,-8533000.0,-4435000.0,15383000.0,603000.0,383000.0,-3885000.0,-14833000.0,386000.0,2943000.0,-4418000.0,15000000.0,,198430000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,-1.61,-4.9130435,-25.04,7.981111,-0.0711112,-0.008909938,15.786522,-7.876522,-0.49893966,270673856,-18.395348,-0.31589454,15,America/New_York,EDT,-14400000,False,False,7.91,1630526402,0.19000006,7.8,7.915,7.63,107722,POST,NMS,2,0.0,1630526407,7.91,0.0,2.4611409,7.63 - 7.915,7.72,7.84,8.1,11,10,finmb_416409020,NasdaqGS,"Frequency Therapeutics, Inc.",USD,336321,150450,1.0549998,0.15390223,6.855 - 58.37,-50.46,-0.8644852,6.855,58.37,1617048000,1617048000,1617048000,-10.293,-0.43,0,"Frequency Therapeutics, Inc.",,,,58.37,6.86,7.98,15.79,336.32k,150.45k,34.22M,,29.78M,12.31%,60.44%,5.98M,14,24.37%,17.47%,5.44M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-122.12%,-122.47%,-11.51%,-24.53%,34.37M,1.04,-36.00%,36.98M,-40.78M,-41.97M,-10.29,,194.91M,5.7,46.48M,26.20,10.58,-25.04,-61.3M,-46.61M,Value,02421,Healthcare,83,9,1,"Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.",Lexington,781 315 4600,MA,8,1609372800,1625011200,8,United States,http://www.frequencytx.com,86400,8,75 Hayden Avenue,Biotechnology,Suite 300
t-2,FREQ,199592000.0,34219200,10153000,,-5326000,,-5341000,6512000,11247000,-5418000,-5418000,,-218000,,,,15000,11247000,16665000,0,92000,,-5341000,-5341000,284681000.0,34728000.0,199592000.0,24030000.0,234320000.0,34000.0,-85167000.0,44000.0,1815000.0,224231000.0,32919000.0,44000.0,5162000.0,227343000.0,,,4089000.0,,,-16000.0,-9348000.0,-1017000.0,40605000.0,924000.0,40605000.0,28858000.0,-10730000.0,301000.0,2734000.0,-1001000.0,15000000.0,,194424000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,-1.61,-4.9130435,-25.04,7.981111,-0.0711112,-0.008909938,15.786522,-7.876522,-0.49893966,270673856,-18.395348,-0.31589454,15,America/New_York,EDT,-14400000,False,False,7.91,1630526402,0.19000006,7.8,7.915,7.63,107722,POST,NMS,2,0.0,1630526407,7.91,0.0,2.4611409,7.63 - 7.915,7.72,7.84,8.1,11,10,finmb_416409020,NasdaqGS,"Frequency Therapeutics, Inc.",USD,336321,150450,1.0549998,0.15390223,6.855 - 58.37,-50.46,-0.8644852,6.855,58.37,1617048000,1617048000,1617048000,-10.293,-0.43,0,"Frequency Therapeutics, Inc.",,,,58.37,6.86,7.98,15.79,336.32k,150.45k,34.22M,,29.78M,12.31%,60.44%,5.98M,14,24.37%,17.47%,5.44M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-122.12%,-122.47%,-11.51%,-24.53%,34.37M,1.04,-36.00%,36.98M,-40.78M,-41.97M,-10.29,,194.91M,5.7,46.48M,26.20,10.58,-25.04,-61.3M,-46.61M,Value,02421,Healthcare,83,9,1,"Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.",Lexington,781 315 4600,MA,8,1609372800,1625011200,8,United States,http://www.frequencytx.com,86400,8,75 Hayden Avenue,Biotechnology,Suite 300
t-3,FREQ,161701000.0,34219200,8764000,,-6018000,,-6025000,5959000,8523000,-6200000,-6200000,,-218000,,,,7000,8523000,14723000,0,182000,,-6025000,-6025000,241436000.0,43085000.0,161701000.0,35523000.0,204786000.0,31000.0,-79826000.0,60000.0,1809000.0,195379000.0,41165000.0,60000.0,4553000.0,198424000.0,,,2190000.0,,,3075000.0,-8984000.0,2166000.0,391000.0,2249000.0,391000.0,-7705000.0,-10262000.0,244000.0,2501000.0,-909000.0,15000000.0,-247000.0,157259000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,-1.61,-4.9130435,-25.04,7.981111,-0.0711112,-0.008909938,15.786522,-7.876522,-0.49893966,270673856,-18.395348,-0.31589454,15,America/New_York,EDT,-14400000,False,False,7.91,1630526402,0.19000006,7.8,7.915,7.63,107722,POST,NMS,2,0.0,1630526407,7.91,0.0,2.4611409,7.63 - 7.915,7.72,7.84,8.1,11,10,finmb_416409020,NasdaqGS,"Frequency Therapeutics, Inc.",USD,336321,150450,1.0549998,0.15390223,6.855 - 58.37,-50.46,-0.8644852,6.855,58.37,1617048000,1617048000,1617048000,-10.293,-0.43,0,"Frequency Therapeutics, Inc.",,,,58.37,6.86,7.98,15.79,336.32k,150.45k,34.22M,,29.78M,12.31%,60.44%,5.98M,14,24.37%,17.47%,5.44M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-122.12%,-122.47%,-11.51%,-24.53%,34.37M,1.04,-36.00%,36.98M,-40.78M,-41.97M,-10.29,,194.91M,5.7,46.48M,26.20,10.58,-25.04,-61.3M,-46.61M,Value,02421,Healthcare,83,9,1,"Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.",Lexington,781 315 4600,MA,8,1609372800,1625011200,8,United States,http://www.frequencytx.com,86400,8,75 Hayden Avenue,Biotechnology,Suite 300
